CJC-1295 without DAC

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

No established clinical evidence for this defined material. A clinical benefit and a complete safety picture have not been established for the defined material or use reviewed here.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

FDA found no studies establishing the pharmacological activity of the non-DAC substance and no adequate nonclinical safety package. Similarity to GHRH or to the DAC molecule is not a substitute for direct evidence.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Research only

  CJC-1295 without DAC is not FDA approved. FDA separately evaluated the non-DAC free base and acetate and concluded that evidence was insufficient for 503A bulks-list inclusion.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• CJC-1295 with DACThe non-DAC molecule is distinct from the albumin-binding DAC form studied in early human trials.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   FDA briefing document for CJC-1295-related substances

   U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: CJC-1295-related substances. 2024.

   U.S. Food and Drug Administration · Published Oct 29, 2024 · Accessed Jul 22, 2026 · Regulatory source

   Open source